Disclosed are four compounds: 5-{ 3-Fluoro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl} -N,N-dimethylpyridine-2-carboxamide 5-{ 3-Fluoro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl} -N-methylpyridine-2-carboxamide N-Ethyl-5-{ 3-fluoro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl} pyridine-2-carboxamide 5-{ 3-Chloro-4-[(5S)-2-(cis-4-hydroxycyclohexyl)-1-oxo-2,7-diazaspiro[4.5]dec-7-yl]phenyl} -N-ethylpyridine-2-carboxamide and pharmaceutically acceptable salts thereof. The compounds are useful for: inhibiting activity of 11bHSD, the conversion of cortisone to cortisol in a cell, inhibiting the production of cortisol in a cell, and for treating obesity, diabetes, glucose intolerance, insulin resistance, hyperglycaemia (hyperglycemia), hypertension, hyperlipidaemia (hyperlipidemia), cognitive impairment, depression, dementia, glaucoma, cardiovascular disorders, osteoporosis, inflammation, metabolic syndrome, androgen excess or polycystic ovary syndrome (PCOS).
